In Q1 2025, Tang Capital Management held 148 positions worth $1.6B. They initiated 13 new positions and exited 55. Their largest holding was TARS ($126.1M). Portfolio value grew +21.4% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q1 2025?
Tang Capital Management held 148 biotech stocks in their 13F portfolio in Q1 2025. Their top positions include TARS, GLPGF, AUPH, DVAX, EOLS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q1 2025?
Tang Capital Management's tracked biotech portfolio was worth $1.6B across 148 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q1 2025?
Tang Capital Management initiated 13 new positions in Q1 2025, including SYRE, KROS, PLRX, VERA, VIR and 8 more. They also increased 63 existing positions.
What did Tang Capital Management sell in Q1 2025?
Tang Capital Management fully exited 55 positions in Q1 2025, including STIM, NKTR, LIANY, GOSS, WGSWW and 50 more. They also trimmed 21 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →